Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
Key Highlights
- ➤Niki BioSolutions (NIKI) subsidiary signs APOE genotyping agreement with Charter Research
- ➤Charter Research sites gain access to CAP-accredited, NYS CLEP-approved testing platform
- ➤Testing supports Alzheimer’s trial eligibility, safety monitoring, and risk stratification
- ➤Charter Research operates centers in Florida and Illinois across multiple disease areas
Expert Statements
Alidad Mireskandari, President and COO of Niki BioSolutions
“APOE status has moved from a research target to a practical necessity in Alzheimer’s trials. It informs who enrolls, how participants are monitored, and how results are interpreted, making it a routine but critical step in how these studies are designed and run,”
Alidad Mireskandari, President and COO of Niki BioSolutions
“We are pleased to support Charter Research’s investigators and the study participants at their centers, and we see this agreement as another step in building Niki BioSolutions into a trusted testing resource for serious disease research”
Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer’s clinical research network
PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through advanced genomic and biomarker testing, today announced that DiamiR Biosciences, its wholly owned subsidiary, has signed an agreement to perform apolipoprotein E (APOE) genotyping for Charter Research, a multi-site clinical research organization that conducts trials in Alzheimer’s disease, Parkinson’s disease, metabolic liver disease, psychiatric conditions, and weight management.
Get started
Create a free account to read the full story.